• QIAGEN launches QIAstat-Dx Gastrointestinal Panel 2 and Meningitis/Encephalitis Panel,  joining the Respiratory SARS-CoV-2 Panel 
• QIAstat-Dx system uses multiplex real-time PCR, detecting multiple pathogens  simultaneously, providing Ct values and amplification curves for better-informed clinical  decisions 

• QIAstat-Dx solutions will enable efficient and timely patient-centered care for communicable  diseases

The QIAstat-Dx system is designed for use in laboratories and employs cost-efficient, single-use cartridges  with all reagents on board and built-in sample processing. Utilizing multiplex real-time PCR, it detects and  differentiates between multiple pathogens. QIAstat-Dx additionally provides easy-to-view cycle threshold  (Ct) values and amplification curves that can offer additional insights not available with end-point PCR or  other techniques. 

“QIAGEN’s QIAstat-Dx panels provide medical professionals in India with a powerful tool for rapid and  accurate diagnosis of infectious diseases, improving patient outcomes and reducing the burden on  healthcare systems,” said Manoj Jagathmohan, Director & Head, India and South Asia at QIAGEN . 

The QIAstat-Dx Meningitis/Encephalitis Panel analyzes 15 viral, bacterial and fungal pathogens in patients  with suspected central nervous system infections simultaneously and provides results in just 80 minutes,  enabling clinicians to select appropriate therapies in a timely manner. The test boasts high sensitivity and  specificity, addressing an urgent need for rapid and reliable diagnosis of these life-threatening infections. 

The QIAstat-Dx Gastrointestinal Panel 2 can identify 22 clinically relevant bacterial, viral, and parasitic  pathogens that cause most GI infections in about an hour. This panel offers significant advantages over  traditional microbiological testing, which often requires samples to be incubated for at least 24 hours and  up to 10 days. 

The QIAstat-Dx Respiratory SARS-CoV-2 Panel can detect 23 viral and bacterial pathogens causing  respiratory infections. This panel is particularly relevant in India, where respiratory diseases are among the  most prevalent communicable diseases. 

QIAstat-Dx is available in two formats: The QIAstat-Dx version that brings together up to four Analytical  Modules into one integrated system, and the QIAstat-Dx Rise higher-capacity version that provides  comprehensive testing for up to 160 tests per day using eight Analytical Modules. 

With a QIAstat-Dx Connectivity plan, QIAstat-Dx connects to the QIAsphere cloud-based platform that  provides remote monitoring of the instruments and test status, allowing customers to receive push  notifications on their personal devices. It can monitor an unlimited number of instruments across different  hospitals or satellite labs, reducing system downtime and enabling fast and accurate syndromic testing.  Connectivity is achieved through the Qbase hub, which can be connected to QIAstat-Dx in minimal time  through hospitals’ LAN or Wi-Fi networks, ensuring sensitive patient data remains within the hospital  network. 

QIAstat-Dx solutions and syndromic tests to support diagnosing diseases are available in more than 100  countries worldwide. More than 3,500 cumulative systems were installed worldwide at the end of 2022.